NCT03624322View on ClinicalTrials.gov

Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 5, 2018

Primary Completion Date

October 3, 2018

Study Completion Date

October 3, 2018

Conditions
Acute Agitation
Interventions
DRUG

Zyprexa IM

5mg

DRUG

Zydis

10mg orally disintegrating wafer

DRUG

INP105

Single, ascending doses of 5, 10, or 20mg capsules OLZ (olanzapine) or placebo (MCC)

DEVICE

I231 POD® Device

Precision Olfactory Delivery (POD) device

Trial Locations (1)

3004

Nucleus Network Pty Ltd, Melbourne

Sponsors
All Listed Sponsors
lead

Impel Pharmaceuticals

INDUSTRY